The appropriate use criteria process synthesizes evidence-based medicine, clinical practice experience, and expert judgment. The American Academy of Dermatology in collaboration with the American College of Mohs Surgery, the American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery has developed appropriate use criteria for 270 scenarios for which Mohs micrographic surgery (MMS) is frequently considered based on tumor and patient characteristics.

Despite definitive surgical treatment, a subset of cutaneous squamous cell carcinomas (cSCC) has an increased risk of regional/distant metastasis making it challenging to identify patients most at risk.1 The 40-gene expression profile (40-GEP) prognostic test improves risk stratification for patients with cSCC with known clinical or histologic risk factors, stratifyingpatients’ risk of metastasis as low (Class 1), higher (Class 2A), or highest (Class 2B) risk.